In Profile: BeiGene’s John Oyler
John Oyler, co-founded the Beijing-based biotech BeiGene in 2010 with the idea of building a global biopharmaceutical company in China and running clinical trials of an international standard there. With…
Founded in 1988, the China Pharmaceutical Innovation and Research Development Association (PhIRDA) is registered as a non-profit organization by the Ministry of Civil Affairs of China at the first national level. PhIRDA will exert great effort on “academia-industry collaboration”, which centres on the principle of “innovation, industrialization, internationalization” and persists in innovation to achieve unmet clinical requirements.
Currently, PhIRDA has 142 members, which mainly consist of five major categories: First, start-up and R&D enterprises focusing on innovation of pharmaceutical products; Second, domestic first-class universities, colleges and research institutions conducting pharmaceutical research and development; Third clinical institutions featuring high skills in applicable research on new drugs, especially those that undertake “major new drug innovation” technological platform for good clinical practice; Fourth, investment institutions committing to pharmaceutical innovation; Fifth, national pharmaceutical enterprises excelling at innovation; Moreover, PhIRDA has established a Drug R&D Specialty Committee, Clinical Research Specialty Committee, Medicinal Policy Specialty Committee and Pharmaceutical Innovation Investment Specialty Committee, in order to promote innovation as the goal of organizational structure.
PhIRDA is also a member of International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) to continuously broaden channels of international collaboration.
Contact
Address: Room 601, CTYS Plaza, No. 5 Dongzhimen South Street, Dongcheng District, Beijing, P.R. CHINA
Tel: +86 10-58156353
Email: luxt@phirda.com, ruanxx@phirda.com
John Oyler, co-founded the Beijing-based biotech BeiGene in 2010 with the idea of building a global biopharmaceutical company in China and running clinical trials of an international standard there. With…
A roundup of some of the biggest pharma and biotech news from China including the collaboration between Elektr and Sinopharm; Biocytogen’s partnership with Janssen and deal with Chipscreen Biosciences; China’s…
In light of ongoing geopolitical tension, a globally unfavourable macroeconomic environment and new drug-pricing legislation in the US, at the recent BIO CEO and Investor Conference industry stakeholders evaluated the…
Vaccinating the elderly has been a key factor in ensuring protection against fatality during COVID-19, writes Bridge Consulting’s Stefania Jiang. However, the experience of it in China has been one…
A roundup of some of the biggest pharma and biotech news from China including the approval of two domestically developed COVID treatments; Daewoong’s idiopathic pulmonary fibrosis licensing deal, Roche’s gastric…
One of China’s leading vaccine manufacturers, CanSino Biologics has taken massive strides since its foundation in 2009 and has secured approvals in several countries for its ebola, meningitis, and COVID-19…
A roundup of some of the biggest healthcare and pharma news from China including the exclusion of Pfizer’s Paxlovid from the country’s national insurance coverage, CanSino’s promising mRNA booster trial…
A roundup of some of the biggest healthcare and pharma news from China, including the country’s struggle with a rampant COVID-19 outbreak and the external concern that surrounds it, China…
Writing in the special December 2022 edition of DIA’s Global Forum magazine – which focuses exclusively on decentralised clinical trials – on behalf of the DIA China Digital Health Community…
Accestra Consulting’s Zhao Lu* looks back on a year in which China’s Center for Disease Evaluation (CDE) rejected a record-breaking number of drug applications, explores some of the main reasons…
China’s strict ‘dynamic COVID-zero’ policy, relying on lockdowns, mass-testing and border controls to stamp out COVID-19 outbreaks wherever they appear, has undoubtedly constricted the country’s economic growth and prompted uncommon…
DIA Global Forum’s annual review of new drug approvals in China has shown growth in both the number and types of new drugs approved in China from 2019 through 2021:…
See our Cookie Privacy Policy Here
